Clearance authorizes the commercial marketing of Encora X1 as a prescription wearable device to aid in the relief of hand tremors in the treated limb during stimulation in adults with essential tremor (ET).
The X1 device joins the wrist-worn, tremor-treating device market alongside the likes of Cala and Fasikl.
Encora X1, a non-invasive neurostimulation device, comes in at roughly the size of a typical smart watch. It senses tremor rhythm and delivers a customized stimulation that disrupts the tremor signal. This provides patients with stability and improved motor control during daily activities.
The device utilizes proprietary algorithms to analyze tremor and deliver targeted stimulation. Lightweight and discreet, the company says the device seamlessly integrates into daily life.
Alli Davanzo, co-founder and VP of business operations at Encora, said the device. “offers a non-surgical, drug-free alternative, allowing patients to manage their symptoms on their own terms.”
“This clearance represents the culmination of rigorous research and patient-centric design,” said Nadim Yared, CEO of Encora Therapeutics. “We are eager to bring this novel solution to patients who have long waited for more options.”
